Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT03586921 Completed - Depression Clinical Trials

Primary Care Group Therapy for Depression/Anxiety for Women in Petropolis

Start date: May 19, 2006
Phase: Phase 3
Study type: Interventional

This is a randomized controlled trial comparing two groups: 1) Enhanced usual care and 2) Enhanced usual care plus group psychological intervention. In both groups a "stepped care" approach was used to the management of anxiety and depression among women seen in primary care.

NCT ID: NCT03586427 Recruiting - Clinical trials for Depressive Disorder, Major

AGN-241751 in the Treatment of Major Depressive Disorder

Start date: June 13, 2018
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy at 1 day post initial oral dose of AGN-241751 compared with placebo in participants with MDD

NCT ID: NCT03580967 Not yet recruiting - Clinical trials for Major Depressive Disorder

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

Start date: August 1, 2018
Phase: Phase 4
Study type: Interventional

This study will enroll participants who have been diagnosed with type 2 diabetes and are experiencing symptoms of depression. This study will look at an anti-depressant medication called vortioxetine (Trintellix). Vortioxetine is an oral medication (pill) that has been approved by the US Food and Drug Administration (FDA) to treat depression in adults. The purpose of this study is to look at what effects (if any) vortioxetine may have on symptoms of depression in patients with type 2 diabetes. This study will also look at what effects (if any) vortioxetine has on blood sugar, and how vortioxetine may improve the way our brains are able to adapt and respond to stress.

NCT ID: NCT03573713 Active, not recruiting - Clinical trials for Depression, Postpartum

Decreasing Stunting by Reducing Maternal Depression in Uganda: A Cluster Randomized Controlled Trial (CRCT) for Improved Nutrition Outcomes

Start date: September 11, 2017
Phase: N/A
Study type: Interventional

The project seeks to test the integration of Interpersonal Psychotherapy for Groups within Care Group projects and investigate whether the treatment of maternal depression with Interpersonal Psychotherapy for Groups improves the adoption of nutrition-related behaviors that can reduce stunting in the Kitgum District in northern Uganda. A secondary aim is to examine whether the participation in the care groups will also result in remission of depression as a non-specific therapeutic effect although it may not be intended as an antidepressant treatment.

NCT ID: NCT03573349 Not yet recruiting - Clinical trials for Major Depressive Disorder

Glutamate MRS During Ketamine Infusion

Start date: August 2018
Phase: Early Phase 1
Study type: Interventional

This is a feasibility study and the goal of this project is to evaluate whether ACC glutamine, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical remission, Montgomery Asberg Depression Rating Scale (MADRS) total score of =9, to the anti-glutamatergic antidepressant ketamine. As MRS is expensive, we also aim to study a correlation between peripheral glutamate and central glutamate level.

NCT ID: NCT03572790 Not yet recruiting - Depression Clinical Trials

Effects of Seven Day Prucalopride Administration in Healthy Volunteers

Start date: June 2018
Phase: N/A
Study type: Interventional

This study will investigate whether seven days administration of the serotonin receptor subtype 4 (5-HT4) partial agonist prucalopride has effects on emotional processing and neural activity in healthy volunteers, compared to placebo administration. Using an experimental medicine approach, the effects of prucalopride on cognitive biomarkers of antidepressant action will be characterised. In a double-blind design, participants will be randomised to receive seven days administration of either prucalopride (1mg daily) or placebo. All participants will come for a Screening visit, Research Visit One (including an MRI scan) and Research Visit Two (including measures of emotional processing and non-emotional cognition). The primary study hypothesis is that seven-day prucalopride administration will have positive effects on emotional processing and reward sensitivity. A secondary hypothesis is that seven-day prucalopride administration will alter non-emotional cognition. Finally, the study will test the hypothesis that seven day prucalopride administration will alter neural activity during an emotional faces task and a memory task.

NCT ID: NCT03571412 Completed - Clinical trials for Major Depressive Disorder

Antidepressive Effect on 5 Herz (Hz) rTMS Over Dorsomedial Prefrontal Cortex and Left Dorsolateral Prefrontal Cortex

Start date: August 8, 2016
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of 5Hz repetitive Transcranial Magnetic Stimulation (rTMS) over Left Dorsolateral Prefrontal Cortex and Dorsomedial Prefrontal Cortex on Major Depressive Disorder (MDD).

NCT ID: NCT03569475 Recruiting - Clinical trials for Major Depressive Disorder

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder

Start date: July 6, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran compared with placebo in pediatric outpatients (7-17 years) with major depressive disorder (MDD)

NCT ID: NCT03567681 Enrolling by invitation - Bipolar Depression Clinical Trials

Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression

Start date: June 13, 2018
Phase: Phase 4
Study type: Interventional

Consenting subjects with Bipolar depression will remain under the care of their local (psychiatric) care provider and be randomized to a six week course of one of two forms of oxcarbazepine (extended release or immediate release. Study outcomes will be assessed based on outcome measures administered to the subject at home by a computer simulated rater. Local care providers will receive "pre-assessment" reports ahead of each clinical visit, rate the Clinical Global Impression for Severity, and evaluate adverse effects. The primary outcome variable is "treatment effectiveness" operationally defined as the response rate X the completion rate.

NCT ID: NCT03564067 Recruiting - Clinical trials for Major Depressive Disorder

MARt-Depression Trial

Start date: July 5, 2018
Phase: N/A
Study type: Interventional

This is an open label pilot feasibility study that will recruit 15 participants. The purpose of the pilot study will be to evaluate the feasibility of open label Transcranial direct current stimulation (tDCS) in combination with computerized cognitive behavior therapy (cCBT) to maintain wellness following an acute course of Electroconvulsive therapy (ECT) for up to 6 months.